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ABSTRACT
Genetically engineered mouse models have proven to be essential tools for 
unraveling fundamental aspects of cancer biology and for testing novel therapeutic 
strategies. To optimally serve these goals, it is essential that the mouse model 
faithfully recapitulates the human disease. Recently, novel mouse models for 
neuroblastoma have been developed. Here, we report on the further genomic 
characterization through exome sequencing and DNA copy number analysis of four 
of the currently available murine neuroblastoma model systems (ALK, Th-MYCN, Dbh-
MYCN and Lin28b). The murine tumors revealed a low number of genomic alterations 
– in keeping with human neuroblastoma - and a positive correlation of the number of 
genetic lesions with the time to onset of tumor formation was observed. Gene copy 
number alterations are the hallmark of both murine and human disease and frequently 
affect syntenic genomic regions. Despite low mutational load, the genes mutated 
in murine disease were found to be enriched for genes mutated in human disease. 
Taken together, our study further supports the validity of the tested mouse models 
for mechanistic and preclinical studies of human neuroblastoma. 
INTRODUCTION
Mouse models are essential tools in the study 
of the molecular pathogenesis of cancer. They enable, 
amongst others, the analysis of cooperative genetic 
events, dynamic regulation of perturbed gene expression 
during tumor formation and the study of tumor clonality 
and heterogeneity. Furthermore, facing the emerging 
challenges of combination treatments of novel drugs, 
these models now facilitate close alignment of in vivo 
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preclinical and early clinical studies [1]. One of the 
important issues is to determine to what extent the 
mouse model faithfully recapitulates the human disease 
and therefore how well it may serve as a preclinical 
model. Relevant features to study are tumor localization, 
histology, metastatic pattern as well as genomic features 
such as RNA expression, DNA copy number alterations 
and mutation profiles. 
For almost two decades, only one transgenic 
mouse model for neuroblastoma was available (TH-
MYCN). TH-MYCN mice express the human MYCN gene 
under the control of the rat tyrosine hydroxylase (Th) 
promotor [2], which results in neuroblastic tumors in 
about 50% of transgenic animals. This model delivered 
many valuable insights into neuroblastomagenesis 
[3]. Recently, a novel MYCN Cre-inducible transgenic 
mouse model was established, driving MYCN expression 
from the Dbh promotor integrated into the murine 
ROSA26 locus (LSL-MYCN;Dbh-iCre) [4]. This model 
has a relatively high penetrance of tumor formation (> 
75%). It also overcomes some of the limitations of the 
TH-MYCN mouse model, as tumor localization more 
closely resembles the human disease. Moreover, two 
novel bona fide neuroblastoma oncogenes have been 
identified, ALK and LIN28B, that are sufficient to drive 
tumor formation when overexpressed in the neural crest 
or seem to increase the oncogenic potential of MYCN 
overexpression [5–8]. 
Whole exome and genome sequencing studies in 
human primary neuroblastoma provided the first insights 
into the genome-wide mutational spectrum of this tumor. 
Overall, similar to findings in other embryonal tumors, 
mutation frequency was very low with an average of 12 
protein coding gene mutations per individual case [9]. 
ALK mutations were detected in approximately 10% of 
cases, in keeping with previous reports  [10]. Pathway 
analysis of the rare variants in neuroblastomas showed 
enrichment for genes implicated in neuritogenesis [9]. 
All other mutations were found at lower frequency 
except for ATRX mutations that were observed in 
up to one third of cases in older children (>  6 years 
old) and young adults [11]. ATRX was also frequently 
altered due to inactivating structural changes such as 
deletions. Taking into account both gene copy number 
and mutation status, a somewhat higher incidence 
of alterations of 11% was reported for ARID1A and 
ARID1B [12]. Unexpectedly, a similar combination 
of genomic analyses revealed activating alterations 
at or near the TERT locus in 20% of the high risk 
cases, almost exclusively MYCN non-amplified cases 
with normal ATRX status [13]. Rare, but functionally 
relevant mutations in bona fide cancer genes were also 
detected such as the BRAFV600E and NRASP44L hotspot 
mutations, hinting at the importance of RAS signaling 
in a fraction of human neuroblastomas [14]. In relapsed 
neuroblastoma, up to 78% of cases showed mutations in 
RAS/MAPK pathway genes, pointing at a role in tumor 
aggressiveness and therapeutic failure [15, 16].
Here, we describe DNA copy number and whole 
exome mutation analysis in a total of 36 matched 
tumor/normal samples from genetically engineered 
neuroblastoma mouse model systems driven by MYCN 
[2, 4], ALKF1174L [5], MYCN/ALKF1174L or Lin28b [6]. 
Our findings confirm the low incidence of single base 
pair mutations and reveal recurrent DNA copy number 
alterations as observed in the human counterpart. Mutation 
load correlates with the age of onset of tumor formation, 
with absence of mutations in the most rapidly developing 
MYCN/ALKF1174L and Lin28b driven mouse tumors. In 
one Th-MYCN driven tumor, a bi-allelic Dicer1 missense 
mutation known to affect the activity of the RNAse III 
domain was observed, reducing 5p end processing of pre-
miRs including reduced levels of miRNAs of the let-7 
family. Together with the proven driver role of LIN28B, 
this unique observation further supports the central role 
for let-7 in neuroblastoma development.
RESULTS
Low numbers of mutations revealed by exome 
sequencing 
On average, 86.29 million (stdev 37.84 million) 
reads per sample mapped to the murine genome. This 
resulted in an average coverage of 81.62 fold (stdev 
35.96, median 62.61) and a total of 85.01% (stdev 
6.9%) of coding bases of the murine genome reaching a 
coverage of > 20 fold. Details per sample are indicated in 
supplementary Table 1. 
We found an average of 2.87 somatic mutations per 
exome (range 0–24) with an average of 1.06 (range 0– 
10) of these mutations having a possible damaging effect 
on protein function (defined as non-synonymous coding, 
frame shifting or truncating mutations, further referred as 
non-synonymous coding) (see Table 1 for overview). One 
outlier case was observed with 24 mutations, 21 of which 
were located in a 45 Mb stretch on chromosome 7, a region 
heavily affected by copy number changes in this tumor 
suggesting chromothripsis (see Figure 1C, tumor 13 and 14). 
The number of somatic mutations positively correlates with 
the onset of tumor formation (see Figure 2) (rho = 0.588, p = 
1.6x10-4, Spearman’s rank correlation). The Lin28b and Th-
MYCN-ALK driven tumors, which appear earliest, within 60 
days after birth, also have the lowest average mutation burden 
of 0.33 and 0.75 mutations per exome, respectively. The other 
tumor models have a higher average mutation burden of 3.89 
(Th-MYCN), 5.5 (Dbh-MYCN) and 4.75 (ALK) mutations per 
exome and exhibit a longer average time to tumor formation. 
Of particular interest is the observation that cases without 
mutations in the coding genome were observed in each of the 
mouse models. When also considering DNA copy number 
changes, all mouse models have either mutations or copy 
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number changes except for one of the Th-MYCN tumors 
(case 27) and all but three of the MYCN-ALKF1174L double 
transgenic mice tumors that did not accumulate additional 
events during tumor development as determined with the 
methods applied. Supplementary Table 2 contains the non-
synonymous coding and supplementary Table 3 all mutations 
found in all tumors.
Comparative cross species analysis of all 25 non-
synonymous coding mutated genes detected in the mouse 
models resulted in three matches (DICER1, ZNF574 and 
PTCH1, see Table 2C) in the list of 883 genes reported 
to harbor non-synonymous coding mutations in human 
neuroblastoma. Fisher’s exact test (p = 0.086, see Table 
2A) indicates borderline significant overlap.
Table 1: Genomic alterations in murine tumors
Array CGH Somatic exome sequencing
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4 4 ALK 136 whole chromosome 9 (+3;-4;-5;-6;-8;-9;+13;-15;-X) - - 0 0
3 3 ALK 148 segmental 4 (+3;+7;+10;-X) 1 (+11q) 1 4 3
1 1 ALK 130 segmental 2 (+12;-X) 1 (+11q) 3 11 3
5 5 ALK 130 segmental 11 (+3;-4;-5;-8;-9;-13;-14;-15;-18;-19;-X) 1 (-12q) - 4 1
2 2 ALK 197 focal 2 (+3;+12) - 2 (including MYCN) - -
11 7 LSL-Lin28b 56 whole chromosome 1 (+3) - - 0 0
10 7 LSL-Lin28b 56 whole chromosome 3 (+3;+7;+10) - - 0 0
9 7 LSL-Lin28b 56 whole chromosome 1 (+3) 1 (+11q) - 0 0
8 6 LSL-Lin28b 56 segmental 1 (+3) 1 (-14q) - 1 1
7 6 LSL-Lin28b 56 segmental 1 (+3) 1 (-14q) - 1 1
6 6 LSL-Lin28b 56 segmental 1 (+3) 1 (+11q) - 0 0
12 8 LSL-NMYC 89 segmental 1 (+3) 1 (+16p) 1 0 0
13 9 LSL-NMYC 46 focal - - 6 ( all on chromosome 7) 0 0
14 9 LSL-NMYC 46 focal - - 5 (4 on chromosome 7) 24 10
15 10 LSL-NMYC 100 whole chromosome 2 (+3;+6) - 1 0 0
16 10 LSL-NMYC 100 whole chromosome 2 (+3;+6) - 1 1 0
18 12 LSL-NMYC 88 whole chromosome 3 (+3;+6;+12) - - 8 1
17 11 LSL-NMYC 88 segmental 1 (+3) 1 (+11q) 2 0 0
24 18 TH-MYCN 86 flat - - 0 (skint gene locus) 6 3
20 14 TH-MYCN 129 whole chromosome 1 (+3) - 0 (skint gene locus) 16 6
23 17 TH-MYCN 65 flat - - 0 (skint gene locus) 6 2
19 13 TH-MYCN 123 whole chromosome 1 (+3) - 0 (skint gene locus) 0 0
25 19 TH-MYCN 82 flat - - 0 (skint gene locus) 3 0
21 15 TH-MYCN 67 flat - - 0 (skint gene locus) 0 0
22 16 TH-MYCN 95 whole chromosome 2 (+3;-14) - 2 (+ skint gene locus) 0 0
27 21 TH-MYCN 80 focal - - 0 (skint gene locus) 1 1
26 20 TH-MYCN 126 focal 1 (+3) - 3 (+ skint gene locus) 3 1
28 22 TH-MYCN-ALK 25 focal - - 5 3 1
29 23 TH-MYCN-ALK 41 flat - - - 0 0
32 26 TH-MYCN-ALK 29 flat - - - 0 0
31 25 TH-MYCN-ALK 29 flat - - - 3 1
33 27 TH-MYCN-ALK 22 flat - - - 0 0
34 28 TH-MYCN-ALK 22 flat - - - 0 0
35 29 TH-MYCN-ALK 33 whole chromosome 1 (+10) - - 0 0
36 30 TH-MYCN-ALK 33 flat - - - 0 0
30 24 TH-MYCN-ALK 32 flat - - - 0 0
The genomic alterations found in the murine tumors divided up into array CGH and exome sequencing results. Array CGH profiles where evaluated as having whole chromosomal 
copy number changes, segmental (large chromosomal sections) or focal alterations. For the chromosomal and segmental alterations, we indicate the chromosome or region altered, 
a + means a gain while a – indicates a loss of chromosomal material. For the focal alterations, we list the number of alterations found. In the exome sequencing columns, we list 
the total number of mutations and the number of mutations predicted to have a consequence at the protein level.
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Recurrent and syntenic DNA copy number 
alterations observed 
All but 10 of the murine tumors harbor copy number 
alterations as determined by arrayCGH (see Figure 1). The 
most frequently recurring alteration is a whole chromosome 
gain of chromosome 3. This specific alteration was 
previously described in the Th promoter driven MYCN 
murine model as occurring in up to 40% of the cases but its 
relevance remains elusive [17]. In our analysis, we confirm 
this high frequency in MYCN (7/15 cases), ALK (4/5 of 
cases) and Lin28b (6/6 of cases) driven neuroblastoma 
models. Murine chromosome 3 is syntenic to several human 
chromosomes, with the centromeric region of chromosome 
3 syntenic with chromosome bands 1p31.2 to 1q32.1. This 
region is in part overlapping the region that is known to be 
gained in MYCN amplified neuroblastoma [18].
Of note is the high number of segmental 11q gains 
across the model systems (5/36 tumors). This region 
is syntenic to the entire human chromosome 17 that is 
the most frequently observed gained chromosome in 
neuroblastoma [18]. An overview of the copy number 
alterations found in the tumors is given in Table 1.
We did not find any evidence of Tert rearrangements 
as only one whole mouse chromosome 13 gain and one 
loss were found in 2 tumors. No focal alterations at the 
murine Tert locus at 13qC1 were observed. The resolution 
of our study however is low for detection of copy number 
events and copy number neutral events (translocations) are 
undetectable by array CGH.
Enrichment of human tumor alterations 
observed in MYCN driven neuroblastoma  
model system 
The MYCN driven murine neuroblastoma tumors 
all harbor additional genomic alterations. A mean of 5.5 
mutations per sample is found in the 15 tumors with a 
Table 2: Cross genomics analysis for mutations found in murine tumors
A: for all murine tumors 
Murine
p-val Fisher’s exact test: 
0.0865
non-synonymous 
mutations not mutated total
Human
non-synonymous 
mutations 3 880 883
not mutated 22 20021 20043
total 25 20901 20926
B: for MYCN driven tumors
Murine
p-val Fisher’s exact test: 
0.0278
non-synonymous 
mutations not mutated total
Human non-synonymous mutations 3 880 883
not mutated 13 20030 20043
total 16 20910 20926
C: overlapping mutated genes
Murine 
gene 
name
 Ensembl murine gene ID Relation Human gene name
Ensembl Human 
gene id
Consequence in 
murine model
Dicer1 ENSMUSG00000041415 ortholog_one2one DICER1 ENSG00000100697 missense
Zfp574 ENSMUSG00000045252 ortholog_one2one ZNF574 ENSG00000105732 missense
Ptch1 ENSMUSG00000021466 ortholog_one2one PTCH1 ENSG00000185920 missense
We explored enrichment of the mutations found in murine tumors for genes known to be mutated in human neuroblastoma. 
From Table 2A we can see the number of overlapping genes (3) to not be enriched (0.0865 Fisher’s exact test) for genes 
mutated in human neuroblastoma 883 for a total of 25 genes showing mutations in the murine tumors. If we restrict this 
analysis to the MYCN driven tumors we do achieve significance (0.0278 Fisher’s exact test) as 3 out of 16 genes mutated in 
murine tumors show overlap with the genes mutated in human neuroblastoma. In Table 2B we show the murine and human 
name and ids for the genes showing mutations in both murine and human tumors.
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Figure 1: Murine tumor kayo views: DNA copy number profiles of murine tumor samples. Gains are indicated in blue, 
losses in red (A. ALK F1174L, B. Lin28b, C. LSL-MYCN, D. Th-MYCN E ALK F1174L/MYCN).
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range of 0 to 24 mutations. All but one tumor showed 
at least one, but mostly multiple whole and/or partial 
chromosomal copy number alterations. Of particular 
interest is the large number of whole chromosome 3 
gains in 7 out of 15 (46%) cases in this series. Also, a 
focal region of structural variation (multiple gains and 
losses) on chromosome 4, not observed in the other mouse 
models, was present in all Th-MYCN driven tumors. 
As we observed this structural alteration in all tumors, 
this may be the result of the insertion site of the MYCN 
transgene. This defect has not been described in previous 
copy number studies of this model system, possibly due to 
the limited resolution of the BAC clone based microarray 
of the previous analyses [17]. The location of this focal 
copy number change hotspot overlaps with the Skint gene 
cluster, a frequent locus for genomic rearrangements.
Mutations previously reported in human 
neuroblastoma were enriched in the MYCN driven 
mouse tumors (see Table 2B) (p-value of 0.0278, 
Fisher’s exact test). Of particular interest, a bi-allelic 
Dicer1 mutation (see Figure 3) conferring a glycine 
substitution at position 1804 and 1807 was observed 
in one single mouse tumor. This mutation is known 
to cause a loss of negative charge in the magnesium-
binding pocket of the RNAse IIIb domain of both the 
murine Dicer1 and human DICER1 protein and has 
been reported as recurrent mutation in ovarian germ 
cell tumors. This results in preferential processing of 3p 
versus 5p miRNAs [19]. We observed this phenotype 
in the murine tumor that harbors the biallelic dicer 
mutations by small RNA sequencing. When calculating 
the average ratio of mature 3p to 5p expression for each 
pre-miR we observed a value of 1.02 for the Dicer1 
mutant tumor and significantly (z-score 6.71, p-value 
9.24x10-12) lower values of 0.97, 0.95 and 0.95 in three 
control tumors (two MYCN driven, one Lin28b driven, 
all of them not harboring Dicer1 mutations). The bi-
allelic Dicer1 mutations co-occurred together with 15 
other mutations including six non-synonymous coding 
ones and a whole chromosome 3 gain. 
In one Dbh-MYCN tumor that harbors whole 
chromosome gains in chromosomes 3, 6 and 12, we 
observed a total of eight mutations of which one was a 
non-synonymous coding mutation. The latter mutation 
is occurring in the Ptch1 gene known to play a role in 
the hedgehog signaling pathway involved in neuroblast 
differentiation [20]. A p.A300D missense mutation in 
the PTCH1 gene was previously reported in human 
neuroblastoma [12], suggesting that missense mutations 
could impair neuroblast differentiation and cooperate in 
MYCN driven tumor formation. 
The third gene mutated in both murine and human 
neuroblastoma is ZNF574 (murine ortholog Zfp574). The Th-
MYCN driven tumor which harbors this mutation is showing 
Figure 2: Number of genomic alterations per tumor correlates with tumor age of onset. The number of somatic murine 
genomic alterations plotted against the age of the mouse at tumor onset showing a positive correlation. This correlation is also observed 
in human tumors [9]. The correlation is not strong but highly significant as indicated by the Spearman’s rank correlation rho and p values.
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Figure 3: Bi allelic Dicer1 mutation. Bi-allelic Dicer1 mutation (A) IGV view of DICER1 mutated residues in tumour case 20: all but 
one read (with multiple mismatches and low mapping quality) show only one mismatch which indicates a bi allelic mutation in this tumor. 
(B) mutated residues which are shown as sticks (in blue) are located at the surface of the protein, and bind together with Glu1699, Asp1703 
and Asp1707 Mg (red balls). PDB-entry 3C4B [58] is shown in blue, PDB-entry 2EB1 [60] is shown in yellow.
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a total of 6 mutations of which 2 are non-synonymous (the 
second one in an olfactory receptor gene, likely a passenger 
mutation). Copy number analysis of this tumor reveals only a 
small number of focal deletions in its genome.
Two tumors of the Dbh-MYCN model in this set are 
derived from the same mouse and are designated “multiple 
primaries” as they occur in the left and right adrenal 
glands, which would not be a typical metastatic spread of 
an adrenal derived tumor. We sequenced both tumors and 
noticed a similar complex pattern in chromosome 7 copy 
number changes. Metastatic spread of one primary tumor 
thus seems a more likely explanation for the multiple 
tumors observed in this mouse. Of the 24 mutations 
observed in the left adrenal mass, as many as 19 occurred 
on chromosome 7, and 17 reside within a single gene 
(C2orf78), located in a region of extensive chromosomal 
rearrangements. A possible explanation for this is the 
occurrence of chromothripsis, a complete shattering of 
a single chromosome also described to occur in primary 
human neuroblastoma [9, 21].
We have confirmed the occurrence of whole 
chromosome 6 gains previously reported in this model 
system with partial synteny to human chromosomes 7p, 7q 
and 12p [4]. Gains in chromosome 7 have been described 
to occur frequently in human neuroblastoma.
Of note is that loss of chromosome 1p is frequently 
reported to co-occur with MYCN amplification in human 
neuroblastoma. The synteny of this human chromosomal 
region is scattered over many of the murine chromosomes 
of which large chunks reside on chromosomes 4 and 5. We 
did not observe any copy number alterations of these two 
chromosomes in the murine tumors but did find a Tp73 
mutation in one of the MYCN driven tumors, this gene is 
located at the human 1p36 region that is frequently deleted 
in high-risk neuroblastoma.
Additional genomic alterations required for ALK 
F1174L driven tumor development in murine model 
system
Activating anaplastic lymphoma kinase (ALK) 
mutations are the most frequent cause of familial 
neuroblastoma [22]. We sequenced four tumors derived 
from the ALKF1174L transgenic murine model  [5]. On top of 
the DNA copy number changes that mimic the aberrations 
known to occur in human neuroblastoma, three out of four 
tumors harbored non-synonymous coding mutations. The 
relatively late onset of tumor formation (on average 136 
days) suggests the requirement of additional oncogenic 
events in addition to mutant ALK. Two tumors show a 
chromosome 11q gain syntenic to human 17q. One other 
tumor shows a chromosome 12 gain with an additional 
focal amplification on that chromosome encompassing 
the Mycn gene locus. One of the 11q gained tumors 
also contains four mutations of which three are non-
synonymous coding. Two of these mutations affect the 
same allele of the Cfh gene, mutated in 340 of 20,238 
cases in the COSMIC database among which many lung 
adenocarcinoma and lung squamous cell carcinomas, a 
disease with a known role for ALK as a tumor driver in a 
subset of cases. Another tumor with whole chromosomal 
gains or losses did not harbor any mutations. Of note, 
efforts to produce more tumors derived from the ALK 
transgenic founder mouse have thus far been unsuccessful. 
Further, the penetrance of tumor formation of the series 
of mice in the original publication was only 50%. These 
observations led us to conduct a detailed search for the 
insertion site of the ALK transgene in the mice forming 
tumors. Paired-end whole genome sequencing has enabled 
us to find at least one genomic integration site for the ALK 
vector construct. Using PCR, we confirmed the insertion 
location to be on chromosome 4 within the Kif1b gene, 
syntenic to the human gene with the same name that maps 
to the 1p36 chromosomal region, known to be frequently 
deleted in MYCN amplified tumors. Notably, this gene has 
been proposed as tumor suppressor in neuroblastoma as 
it drives cells towards apoptosis upon neuronal growth 
factor withdrawal [23]. Our data thus support a possible 
tumor suppressor function for this gene and also suggests 
that other lesions than ALK activation may be required to 
induce tumor formation. It remains to be determined if 
Kif1b activity is compromised in this mouse model and if 
more than one mutant ALK gene copy is integrated in the 
Kif1b locus or perhaps at other sites.
Low mutation and copy number alteration 
numbers in Lin28b and double transgenic mouse 
neuroblastoma model
Six tumors derived from the Lin28b driven model 
system were included in our analysis. These tumors 
represent multiple primary tumors derived from two 
mice (three each). The tumors were isolated from the 
ganglion ciliare, and the left and right adrenal gland (see 
supplementary Table 4) suggesting they are not metastatic 
spread of a single tumor. Overall, the number of DNA copy 
number changes and mutations in these tumors is very low, 
in keeping with the early onset of tumor formation observed 
in this model system (mean of 56 days in this series). Whole 
chromosome 3 gain was observed in all tumors. Only two 
tumors showed a single mutation, one in an olfactory 
receptor gene (frequent false positive mutation call or 
passenger mutation) and one in the murine ortholog of the 
human PALD1 gene with no known oncogenic function 
(and no mentions in the COSMIC database). Two of these 
tumors show a gain of the 11q genomic region, the murine 
ortholog of human chromosome 17. Another two tumors 
have a 14q deletion in a region homologous to the human 
13q14.3 to 13q33.1 region showing only sporadic gains in 
human neuroblastoma [18].
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A total of eight ALKF1174L/MYCN double transgenic 
mice tumors were studied. These mice developed tumors 
at a mean age of 29 days after birth, which is faster than 
the MYCN or the mutant ALK driven single transgenic 
murine models. In keeping with low mutation burden 
in rapidly developing tumors, these tumors also had 
with very few genomic alterations. With only two out 
of eight samples that show three mutations each (of 
which just a single non-synonymous coding mutation 
per sample) the average mutation count per sample is 
only 0.75 and thus much lower than in both the MYCN 
and ALK single transgenic model derived tumors. One 
of the non-synonymous coding gene mutations found in 
this model system resides in the Chga gene. This gene 
encodes Chromogranin A, a protein co-released from 
catecholamine containing neurosecretory granules and 
expressed in sympathetic neuronal cells. This gene has 
no known tumorigenic or tumor suppressing potential. 
The second gene found mutated in a tumor derived from 
this model system has a mutation in the Sh2d2a gene. 
This gene is involved in immune regulation of T-cells. 
As Sh2d2a T-cell deficient mouse seems to have an 
increased resistance towards tumor formation of B cell 
lymphoma [24], it is unclear how this mutation might 
contribute to neuroblastoma tumor formation. The 
cooperative effect of MYCN amplification and ALKF1174L 
mutation seems to be sufficient to drive malignant 
transformation in neuronal progenitor cells towards 
neuroblastoma tumors.
DICER1 RNAse IIIb domain mutation 
landscape in human neuroblastoma
To further investigate the biallelic Dicer1 mutation, 
we Sanger sequenced the DICER1 RNAse IIIb domain 
in 155 primary neuroblastoma cases and the frequently 
mutated catalytic hotspot in an additional 121 cases. 
Apart from known SNPs, a single E1803D substitution 
was found. While this is not a DICER1 hotspot mutation 
[19, 25], the position is just a few amino acids away from 
the catalytic site and three cases have been described to 
be mutated at this position in the COSMIC and TCGA 
datasets (one colon and two ovarian adenocarcinoma, all 
E1803K substitutions). In addition, a truncating mutation 
in DICER1 was described in a single case of human 
neuroblastoma analyzed by whole genome sequencing 
[9]. No other DICER1 gene mutations have been reported 
in other neuroblastoma sequencing efforts [11, 12, 14]. 
Mutation of the catalytic hotspot of the RNAse IIIb 
domain thus seem to only occur very sporadically in 
human neuroblastoma. However, it has been shown that 
DICER1 can act as a haplo-insufficient tumor suppressor 
gene [26]. In keeping with this observation, DICER1 
is located in chromosome band 14q32.13, a region 
which is known to be frequently affected by deletions 
in neuroblastoma [27, 28] and other tumors. Moreover, 
in neuroblastoma, DICER1 and ARGONAUTE RNA 
expression levels have been shown to correlate with 
survival, with lower expression levels occurring in high-
risk tumors [29]. A truncated DICER1 gene transcript that 
misses part of the RNAse IIIb domain has been reported 
in neuroblastoma cells [30]. We performed a pooled re-
analysis of a large cohort of 498 primary neuroblastoma 
RNA sequencing data [31], thus confirming the expression 
of this transcript in neuroblastoma. However, coverage in 
this dataset was insufficient to determine a per sample 
expression level of truncated DICER1 transcripts. We 
determined the expression of this specific transcript in 
our series of primary neuroblastoma cDNA samples by 
PCR fragment analysis and found its expression to occur 
in 222 of 338 samples tested (65.6%, see Supplementary 
Table 5). Of the samples that express truncated DICER1, 
the average relative expression of the truncated isoform 
to the total DICER1 level is 9.6% with a range of 2.8 to 
39.0%. Expression of this truncated isoform might be 
an alternative mechanism in which neuroblastoma cells 
achieve a molecular effect similar to RNAse IIIb domain 
mutation.
DISCUSSION
Our study is the first extensive evaluation of genome 
wide genetic alterations across four of the currently 
available transgenic murine neuroblastoma models. 
We provide further support that the tumors that arise in 
these mice recapitulate well the human disease in terms 
of genetic alterations. In a previous study, we explored 
the Th-MYCN model in relation to MYCN and Lin28b 
driven microRNA regulation [32]. Here, we focus on the 
occurrence of base pair mutations and DNA copy number 
alterations and show that the mouse tumors recapitulate 
the findings in human primary high-risk neuroblastoma. In 
keeping with sequencing data in human neuroblastoma, the 
mutation burden in mouse neuroblastoma is low and some 
tumors even do not show any detectable alterations using 
the applied methods. Of notice, we observed differences in 
the number of genomic events that depend on the involved 
genomic driver. In particular, Lin28b overexpressing 
tumors exhibited the fewest additional genomic events 
which points at a very strong oncogenic driver effect. 
Likewise, the combined ALKF1174L and MYCN targeted 
overexpression can be sufficient as the sole two genetic 
events to drive neuroblastoma formation while a higher 
number of alterations are observed in the ALKF1174L driven 
cases. This points at an overall weak oncogenic effect of 
ALKF1174L mutations while differences in penetrance may 
be related to different mouse background or can be due 
to transgene integration into a putative tumor suppressor 
gene which thus increases the penetrance or decreases 
onset of tumor formation. Our data thus support the 
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previous observation that mutated ALK in itself does not 
provide sufficient effect to transform sympathetic neuronal 
progenitors in the given mouse genetic background 
while potentiating the oncogenic effect of MYCN 
overexpression as demonstrated by accelerated tumor 
formation  [7, 33]. These findings also underline one of 
the limitations of most currently available model systems 
[3] where uncertainty exists on the insertion location of 
the transgenic vector. This limitation is addressed in the 
LSL-MYCN;Dbh-iCre [4] model system where transgene 
integration in the ROSA26 locus is ensured. 
As reported before, whole chromosome 3 gains are 
a remarkably frequent recurring event in MYCN (46% of 
cases in our series, up to 40% of published cases [17]), 
ALK (80% of cases) and Lin28b (100% of cases) driven 
murine neuroblastoma tumors. Interestingly, chromosome 
3 gain has not been observed in a BRCA1 driven murine 
breast cancer model [34], nor a KRAS driven model of 
non–small cell lung cancer [35] while frequent partial 
gain of this chromosome was described in a MYC driven 
murine model of lymphoma [36]. This might point at the 
importance of chromosome 3 gain in MYC(N) driven 
oncogenesis. 
Our current understanding of the oncogenic role of 
LIN28B in neuroblastoma tumor formation is that it is a 
negative regulator of the let-7 family of miRNAs that 
directly target MYCN [6]. Increased Lin28b activity 
thus contributes to oncogenic MYCN pathway activity. 
Observing the same copy number gains as found in the 
MYCN driven model system (and other MYC driven murine 
cancer model systems [36]) is a strong indicator of the 
role of murine chromosome 3 gene dosage contribution to 
MYCN driven oncogenicity. The short duration until tumor 
formation, the development of multiple primary tumors 
per mouse and the low number of copy number changes 
and mutations found in the tumors indicate that transgenic 
Lin28b overexpression results in a rapidly developing 
highly penetrant murine tumor model requiring little if any 
additional genomic alterations, in keeping with the situation 
in human atypical teratoid rhabdoid tumors [37].
Several of the non-synonymously mutated genes 
found are of interest in neuroblastoma tumor formation. 
Both DCLRE1A and TP73 are involved in DNA repair 
processes. Other genes involved in these processes 
have been described to be mutated sporadically in 
neuroblastoma tumors like the FANCM, FAN1, BRIP1 
and MLH1 genes [9, 14]. The mutation of the double 
strand break repair gene DCLRE1A is of particular 
interest as impairment of the non-homologous end joining 
process is believed to be the cause of the characteristic 
copy number changes in neuroblastoma. Of note, the 
human neuroblastoma showing the DCLRE1A mutation 
is also harboring a complex chromosomal alteration on 
chromosome 7, with multiple copy number changes 
[38]. TP73 on the other hand is part of the p53 family of 
transcription factors involved in response to DNA damage 
and cell cycle arrest. It is one of the highest ranking tumor 
suppressor candidate genes located on the chromosome 
1p36 genomic region showing frequent deletions in 
neuroblastoma [39].
Defects in neuritogenesis are proposed as one 
of the mechanisms involved in neuroblastoma tumor 
formation [9]. The only supporting evidence we found 
in murine tumors is a mutation in the PTCH1 gene 
associated to neural tube formation. As an activator of the 
hedgehog signaling pathway, it plays a role in neuronal 
differentiation [40, 41]. Defects in neuritogenesis probably 
are early events in neuroblastoma tumor formation. 
ASXL1, a gene known to be associated with poor 
prognosis in myeloid malignancies when mutated [42] is 
a ligand binding co-activator of the retinoic acid receptor 
[43]. Retinoic acid has been used as one of the standard 
treatments of neuroblastoma as it induces neuronal 
differentiation. ASXL1 is working in a complex with EZH2 
and SUZ12 as part of the PRC2 complex. It reduces the 
number of H3K27me3 histone marks, resulting in increased 
RAS driven transcription [44], a pathway proven to be 
important in neuroblastoma relapse and chemoresistance. 
Chromatin remodeling genes are recurrently mutated in 
human neuroblastoma  [9, 11, 12, 14].
The occurrence of a bi-allelic hotspot mutation at the 
catalytically important residues in Dicer1 and the subsequent 
reduced processing of 5p derived miRNAs documented by 
small RNA sequencing is strongly suggestive for a functional 
cancer-driving role in the affected tumor. Similar mutations 
in orthologous residues of human DICER1 gene have proven 
biological consequences for miRNA processing and are 
known to be oncogenic [19, 25]. These mutations occur in 
various other human embryonic tumors like Wilms tumor 
[45], non-epithelial forms of ovarian cancer and embryonic 
rhabdomyosarcoma [46]. The neuroblastoma driving 
potential of LIN28B and the occurrence of a bi-allelic Dicer1 
RNAse IIIb domain mutation is indicative of the importance 
of miRNA deregulation in neuroblastoma tumor formation. 
miRNAs are of crucial importance in normal embryonic 
development and an increasing number of embryonic tumor 
types are known to have alterations in the miRNA processing 
machinery [45, 46]. Although they do occur, our data clearly 
shows that DICER1 mutations are not a major mechanism 
of miRNA biogenesis alteration in neuroblastoma. A 
possible alternative mechanism for neuroblastoma cells to 
achieve the same biological effect would be to express a 
truncated DICER1 transcript as previously described [30, 
47] and documented in this study to occur at substantial 
rates in primary neuroblastoma. Whether this transcript 
is neuroblastoma specific and really is contributing to 
neuroblastoma oncogenesis remains to be explored.
Despite the enrichment of genes mutated in human 
neuroblastoma in the MYCN driven model systems we 
studied, we did not find any mutations in some important 
recurrently altered genes involved in neuroblastoma 
biology. Mutations and structural alterations involved in 
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genes regulating telomere maintenance are an important 
emerging theme in neuroblastoma biology. We found 
no evidence in murine tumors of either ARID1A [12] or 
B, ATRX [11] or TERT [13, 48] mutations. However, in 
human neuroblastoma TERT rearrangements rarely, if 
ever, co-occur with MYCN or ATRX alterations [13, 48]. 
Moreover, the methods we applied are not appropriate to 
detect copy number neutral structural variations known to 
cause TERT alterations in human neuroblastoma. Another 
theme that seems to be under represented in murine tumors 
are defects in neuritrogenesis genes like PTPRD, ODZ3 or 
CSMD1 [9]. Alterations in these genes possibly are early 
events in human neuroblastoma development and thus 
are not required for tumor formation in neuroblastoma 
model systems overexpressing a strong tumorigenic driver 
in the neural crest. Overall the low number of recurrent 
mutations in both human and murine neuroblastoma are 
indicative of this disease’s genetic heterogeneity.
An important limitation of currently available 
neuroblastoma murine model systems is that none of them 
seem to adequately represent the metastatic pattern of 
human disease. In our murine dataset, we have not found 
any mutations in genes published to be associated with 
metastatic disease like TRKB, NM23, C-MYB, SLUG1, 
DKK1, NCAM of integrins and selectins [3].
In conclusion, our study further contributes to the 
characterization of four of the currently available genetic 
neuroblastoma mouse models and further supports their 
validity for preclinical studies. Following this analysis, 
further follow up should include RNA sequencing, whole 
genome sequencing and epigenetic profiling in order to 
further characterize the mouse neuroblastoma genome in 
more depth as prelude to currently foreseen drug testing to 
dissect the biological effects of novel treatments in mouse 
and human tumors.
MATERIALS AND METHODS
Mouse model tumors
Tumors were obtained from LSL-Lin28b; Dbh-
iCre (n = 6) [6]; LSL-MYCN;Dbh-iCre (n = 7) [4], Th-
MYCN (n = 9) [2], ALKF1174L; Dbh-iCre (n = 5) [5] and 
Th-MYCN; ALKF1174L; Dbh-iCre (n = 9) [5] model systems. 
Heterozygous state for the transgene of all mice included 
in this study was ensured by cross breeding with wild type 
mice. Tumor characteristics are listed in supplementary 
Table 4.
Human neuroblastoma tumors 
The samples for DICER1 DNA mutation analysis 
were available from the Neuroblastoma Research 
Consortium, a European collaboration of national 
coordinating neuroblastoma research labs in Ghent, 
Belgium; Amsterdam, The Netherlands; Essen, Germany; 
Genova, Italy; Valencia, Spain and Dublin, Ireland. The 
patient characteristics are given in supplementary Table 6. 
Exome sequencing and mutation calling
Murine tumor and constitutional DNA was captured 
using the Agilent SureSelect XT target enrichment system 
for Illumina paired end sequencing. A total of 200 ng of 
input DNA was used per sample. DNA was sheared using 
a Covaris S-series Single Tube Sample Preparation System 
to a target length of 200 bp (duty cycle 10% intensity 5; 
200 cycles per burst for 200 seconds). Subsequently, 
the DNA was purified using Agencourt AMPure beads 
and analyzed on an Agilent Bioanalyzer using the high 
sensitivity DNA assay. After end repair and adapter 
ligation, performed as specified by the manufacturer’s 
protocol, the samples were purified with Ampure Beads 
and then amplified for 6 cycles using Phusion High fidelity 
PCR reagents. Libraries were sequenced on an Illumina 
HiSeq 2000 in 2x 100 bp mode.
Raw sequencing data was demultiplexed on the 
HiSeq instrument using the manufacturer’s software. 
Mapping was performed to build 37 of the murine 
reference genome (Genome reference consortium 
MGSCm37) using BWA [49] (v. 0.5.9). Reads were 
quality recalibrated using the Genome analysis toolkit [50] 
(v. 1.6-13-g91f02df) and duplicate reads were removed 
using Picard tools (v. 1.59). Variants were called using 
the Genome Analysis Toolkit (GATK) unified genotyper 
[50] (v 1.6-13-g91f02df). Variants were annotated and 
sample calls between tumors and controls were compared 
using our custom cloud based analysis platform seqplorer 
(www.seqplorer.org) (De Wilde et al., in preparation). 
Mutations were found by considering the raw read counts 
in the tumor and matching normal sample. Fisher’s 
exact test was calculated on the raw read counts for each 
variant called by the GATK in the tumor sample and 
subsequently multiple testing corrected (according to 
Benjamini Hochberg [51]). A mutation was considered if 
its p-value was significant at the 0.05 level, the percentage 
of variant reads in the normal sample was under 5% and 
the percentage of variant reads in the tumor sample was at 
least 10% higher.
Coverage data was extracted for each sample using 
the samtools depth option. To evaluate capture efficiency, 
we defined the target region as the coding parts of the 
canonical transcript from of all coding genes in the murine 
genome, according to the Ensembl database (release 68). 
The total target region comprised of 196,710 coding 
genomic elements, including 35,131,573 base pairs. 
Whole genome sequencing and transgene 
integration mapping
To find the genomic insert of the mutant ALK 
transgene in the murine genome, we sequenced tail derived 
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DNA from mouse 5 included in this analysis. DNA was 
sequenced as described above, omitting the exome capture 
step. The reference genome was constructed from the 
MGSCm37 genome, adding the fasta sequence of the ALK 
transgene vector as a separate chromosome. We generated a 
total of 167 million reads which, after mapping with stampy 
[52] (version 1.0.13), resulted in a genome wide coverage 
of 8.65 fold with a local coverage of the transgene of 18.34 
fold . Subsequently SVDetect [53] (version 0.7) was used 
in interchromosomal rearrangement mode to identify the 
integration site of the ALK transgene vector.
Cross species genomics analysis
To evaluate the overlap of the genes mutated in 
murine or neuroblastoma disease, we performed a cross 
genomics analysis using the Ensembl cross genomics 
API [54] (build 68). For each gene mutated in murine 
neuroblastoma the Ensembl gene id of the orthologous 
human gene was retrieved. We then searched for overlap 
between this gene list and genes mutated in published 
exome or whole genome sequencing efforts in human 
primary neuroblastoma. As all of the published gene lists 
are restricted to mutations that likely affect the protein 
(non-synonymous coding, frameshift, splice site or 
premature stop codon), we calculated the enrichment score 
with a chi squared statistic for the same type of mutations 
in the murine dataset. Of the 940 genes reported as 
mutated in human neuroblastoma [9, 11, 12], we were able 
to obtain an Ensembl database identifier for 883 of them. 
A total of 20,926 gene pairs were found to be orthologous 
in human and mouse. 
Array comparative genome hybridization CNV 
analysis
DNA was isolated using the DNeasy Blood & 
Tissue Kit (Qiagen) according to the manufacturer’s 
instructions. ArrayCGH was performed using a 180K 
(AMADID 027411) mouse whole-genome arrays (Agilent 
Technologies). Random primed labeling (BioPrime 
ArrayCGH Genomic Labeling System, Invitrogen) was 
used to label 400 ng of tumor DNA and matched control 
DNA with Cy3 and Cy5 dyes (Perkin Elmer), respectively. 
Hybridization and washing were performed according to 
the manufacturer (Agilent Technologies). Fluorescence 
intensities were measured on an Agilent G2505C scanner. 
Data were extracted using the Feature Extraction v10.1.1.1 
software (Agilent Technologies), and further processed 
with ViVar [55]. Gains and losses were determined using 
the circular binary segmentation algorithm [56].
Variant confirmation using sanger sequencing
The mutations found in exome sequencing with 
a predicted effect on protein were confirmed by Sanger 
sequencing whenever primer design was successful. 
Primers were designed for the affected exons involved 
using the primerXL web tool (http://www.primerxl.org). 
10 ng of tumor genomic DNA was amplified in a 25 µl 
PCR reaction using 250 nM of each primer and Bio-Rad 
SsoAdvanced mastermix according to the manufacturers 
protocol. PCR amplicons were Sanger sequenced on a 
ABI Prism 3100 genetic analyser (Applied Biosystems) 
according to manufacturer’s protocol. Trace files were 
interpreted using 4Peaks software (v1.8 http://nucleobytes.
com/4peaks/) and aligned to the genome using the UCSC 
Blat function [57].
Small RNA sequencing
Small RNA libraries were prepared using the TruSeq 
small RNA library prep kit (Illumina) and sequenced on a 
MiSeq instrument (Illumina). Reads were filtered based on 
quality, trimmed and collapsed using the fastx toolkit (v. 
0.0.13). Collapsed reads were mapped to build 38 of the 
murine reference genome (Genome reference consortium 
MGSCv38) using bowtie (v. 0.12.7) and annotated using 
miRBase.
3D modeling of DICER1 mutation
The available structures for DICER1 (PDB-entries 
3C4B and 3C4T [58] were analysed and compared using 
Pymol (The PyMol Molecular Graphics System, version 
1.7.4 Schrödinger, LLC).
DICER1 mutation analysis
The RNAse IIIb domain of the DICER1 gene 
was Sanger sequenced in a series of human primary 
neuroblastoma samples. For PCR amplification, pxlence 
PCR assays were used (http://www.pxlence.com). 10 ng of 
Phi29 amplified DNA (GE Healthcare illustra genomiphi 
v2 kit) was amplified in 25 µl PCR reaction using 250 
nM of each primer and Bio-Rad SsoAdvanced mastermix 
according to the manufacturer’s protocol. PCR amplicons 
were Sanger sequenced by Genewhiz (NY, USA). 
Electropherograms were interpreted using the SeqPilot 
v.4.2.1 (JSI Medical Systems) software.
Truncated DICER1 expression profiling
To detect the expression of DICER1 RNAse IIIb 
lacking isoforms we performed fragment analysis of 
PCR amplicons generated with cDNA primers spanning 
the alternative splicing sites of full length and truncated 
DICER1 as described previously [30]. Fragments 
were amplified on a LC480 instrument (Roche) 
using the SsoAdvanced mastermix (Bio-Rad) in 8 µl 
reaction volume with 250 nM of primer concentration. 
Amplification was performed with 35 cycles of 95°C for 
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30 seconds, 55°C for 30 seconds and 72°C for 40 seconds. 
Amplicons were sized and quantified on a Caliper GX 
capillary electrophoresis system (Perkin Elmer). The 
molar ratio of truncated DICER1 expression over full 
length DICER1 expression was determined using the 
instrument software.
Statistics
Statistical analysis and plotting of data was done 
using the R language and environment for statistical 
computing (R version 2.15.1; www.R-project.org). 
Plots were generated using the ggplot2 package [59]. 
Throughout the manuscript, statistical significance was 
defined as a p-value lower than or equal to 0.05.
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